While good news has rarely come our way over the last year, one of the few bright spots in 2020 that gave us hope for the immediate future were the development of two COVID-19 vaccines by Pfizer/ BioNTech and Moderna.
And while other vaccine candidates from Johnson & Johnson and AstraZeneca have yet to be approved for use in the United States, we had further reasons to breathe sighs of relief when it became clear that the existing vaccines were not only safe but still effective against the coronavirus variants we've seen thus far.
And of course, the promise of securing sufficient vaccine supplies to vaccinate 300 million Americans by July was even more encouraging.
But the ability of members of one of America's most crucial professions to access these vaccines seems to depend on where they live. And from the sound of that, the president is well aware of this fact.